Replies to post #191304 on NorthWest Biotherapeutics Inc (NWBO)

[scotty3371]

20 mos

[flipper44]

flipper44 Member Level Wednesday, 05/30/18 07:45:22 PM
Re: Pablosrv post# 174890
Post # of 191325
Yesterday's DCVax-L article points to the Optune trial and the Rintega trial as having somewhat similar patient populations. Be careful with the Rintega study, as they were looking only at complete resections (minimum residual disease) for the primary endpoint. You'll instead want to use the ITT group, which had about 17 for the mOS for the SOC group (from randomization). In the Optune trial, SOC obtained about 16 mOS (from randomization). The Optune trial was statistically significant, but the Rintega trial was not. Rintega and its "placebo" an adjuvant molecule that stimulates the immune system and has been shown to have anticancer effects even in low doses and using various means of administration. They are referenced in footnotes 21 and 24 in yesterday's publication. Larry Smith's article has a longer list of possible comparable trials, and I think he advises steering clear of the comparison to Rindopepimut's phase III for reasons other than mine.